{"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"50"}],"units":"Participants"}],"groups":[{"description":"The patients receive armodafinil for all 56 days of the study.\n\narmodafinil: Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.","id":"BG000","title":"Armodafinil"},{"description":"These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).\n\narmodafinil: Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.\n\nPlacebo: Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.","id":"BG001","title":"Placebo-First"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"1.8","value":"63"},{"groupId":"BG001","spread":"2.3","value":"67"},{"groupId":"BG002","spread":"2.1","value":"65"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"29"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"37"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"12"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"35"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}],"title":"2"}],"description":"Grade ECOG Performance status\n\n0 Fully active, performance without restriction\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work\n2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours\n3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours\n4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair\n5. Dead","paramType":"NUMBER","title":"ECOG (Eastern Cooperative Oncology Group)","unitOfMeasure":"paarticipants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"39","upperLimit":"83","value":"59"},{"groupId":"BG001","lowerLimit":"36","upperLimit":"79","value":"60.5"},{"groupId":"BG002","lowerLimit":"36","upperLimit":"83","value":"60"}]}]}],"description":"BFI scale: 9 items; range=0-90 (0-10 per item) Mild = 1-3 Moderate = 4-7 Severe = 8-10","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Fatigue (baseline)-Brief Fatigue Inventory (BFI)","unitOfMeasure":"units on a scale"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"6","upperLimit":"12","value":"9"},{"groupId":"BG001","lowerLimit":"6","upperLimit":"12","value":"9"},{"groupId":"BG002","lowerLimit":"6","upperLimit":"12","value":"9"}]}]}],"description":"ICD-10 Criteria (Range: 0-14) A1-A11 Fatigue Criteria B. Clinically significant distress or impaired functioning C. Symptoms are a consequence of cancer or cancer therapy D. Symptoms are a consequence of comorbid psychiatric disorders","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Fatigue (baseline)-International Classification of Diseases version 10 (ICD-10)","unitOfMeasure":"units on a scale"}]}